our results indicated that GAS5 LncRNA may represent a potential biomarker for the diagnosis of lung adenocarcinoma and that GAS5 might play a novel role in the development of the resistance to gefitinib

In this review, we will summarize the current knowledge about LncRNA GAS5, a recently identified tumor suppressor involved in several cancers, like breast cancer, prostate cancer, lung cancer, and colorectal cancer

Discovered a novel long noncoding RNA termed GAS5-AS1 as a tumor suppressor in non-small cell lung cancer (NSCLC). The expression of GAS5-AS1 in NSCLC tumors was much lower than that in the adjacent normal lung tissues. The reduced GAS5-AS1 was significantly correlated with larger tumors, higher TNM stages, and lymph node metastasis in NSCLC patients.

plasma levels significantly down-regulated in nonsmall cell lung cancer patients compared with healthy controls

GAS5 negatively regulated miR-23a expression in non-small cell lung cancer.GAS5 role in the proliferation, invasion, and apoptosis of non-small cell lung cancer.

The results showed that GAS5 decreased in Non-small cell lung cancer (NSCLC) tissues compared to noncancerous tissues (P<0.001). Furthermore, the GAS5 expression level was statistically declined in early stage of NSCLC before surgery compared with healthy controls (P<0.05) and sharply increased in postoperative groups (P=0.026).